Boston Scientific (NYSE: BSX) Navigates Competitive Headwinds Amidst Strong Q2 Results and Positive Outlook

• RBC Capital revised its Boston Scientific (NYSE: BSX) stock price target downward to $70 from $85, citing competitive pressures and a lowered fiscal 2026 financial outlook.
• Despite the reduced forecast, Boston Scientific delivered robust Q2 financial results, with quarterly revenue of $5.442 billion and adjusted earnings per share of $0.86, both exceeding Wall Street analyst estimates.
• Analysts maintain a positive long-term view on BSX stock, highlighting an attractive valuation at 13.7 times forward earnings and potential growth catalysts like the SEISMIQ 4CE coronary catheter.

Boston Scientific (NYSE: BSX) is a leading medical technology company with a market capitalization of around $66.79 billion. The company develops and manufactures a wide range of innovative medical devices used in various procedures. Boston Scientific (NYSE: BSX) faces intense competition but remains a significant player in the dynamic healthcare industry, focusing on strategic innovation and market expansion initiatives.

On July 30, 2026, RBC Capital analyst Shagun Singh reduced the stock price target for Boston Scientific to $70 from a previous $85. At the time, the BSX stock was trading at $44.80. This revised target still represents a potential increase of approximately 56.3% from its price when the new target was set.

This adjustment follows the company's decision to lower its fiscal 2026 financial outlook. Management cited competitive pressures, particularly in its WATCHMAN and Electrophysiology (EP) business segments. As a result, Boston Scientific reduced its adjusted earnings per share guidance for the year to a new range of $3.28-$3.32 per share from $3.34-$3.41 per share.

Despite the lowered forecast, Boston Scientific reported strong Q2 financial results. Quarterly revenue of $5.442 billion and adjusted earnings per share of $0.86 both surpassed Wall Street analyst estimates. As highlighted by Benzinga, the company also announced positive trial results for its SEISMIQ 4CE coronary catheter, a significant new product catalyst for future growth.

Other analysts remain positive, with Seeking Alpha holding a buy rating and a $66 price target. The BSX stock's valuation is seen as attractive at 13.7 times forward earnings. This metric uses future profit estimates to value a company, suggesting the stock may be potentially undervalued relative to its expected performance.